SCHEMBL3109909

SCHEMBL3109909

CC(Cl)c1c(Cl)cccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
NFKB1 P19838 1/20 0.43
PNMT P11086 1/20 0.43
ALDH1A1 P00352 5/20 0.41
LMNA P02545 2/20 0.41
GLA P06280 1/20 0.41
CYP2A6 P11509 2/20 0.41
TSHR P16473 3/20 0.40
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
AKR1B1 P15121 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
PSMB8 P28062 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11090617 0.84 GAA (0.41) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL2353810 0.80 CYP1A2 (0.44) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL279564 0.80 CYP1A2 (0.44) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL5368610 0.77 CYP1A2 (0.45) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL11616735 0.77 CYP1A2 (0.45) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL23212908 0.76 CYP1A2 (0.41) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL2292937 0.76 CYP1A2 (0.41) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL11403685 0.76 CYP1A2 (0.41) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL18242660 0.76 CYP1A2 (0.41) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL19287286 0.76 CYP1A2 (0.41) CYP1A2CYP3A4CYP2D6NFKB1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017541-A1 INHIBITORS OF ARGINASE Praxis Biotech LLC 2022-01-20 US disclosed
US-20220017541-A1 INHIBITORS OF ARGINASE Praxis Biotech LLC 2022-01-20 US disclosed
EP-3883938-A1 INHIBITORS OF ARGINASE Praxis Biotech LLC (US) 2021-09-29 EP disclosed
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed
CN-101827827-A Derivatives of 6-aryl/heteroalkoxybenzothiazoles and benzimidazoles, method for preparing same, use thereof as medicaments, pharmaceutical compositions and novel use thereof, in particular as CMET inhibitors SANOFI AVENTIS 2010-09-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017541-A1 INHIBITORS OF ARGINASE ARG1, ARG2, ARGLU1 CYP1A2 1519/4885CYP3A4 3013/4885CYP2D6 2935/4885
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 CYP1A2 935/4885CYP3A4 324/4885CYP2D6 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.